Zacks Investment Research Downgrades Alpine Immune Sciences (ALPN) to Hold

Zacks Investment Research lowered shares of Alpine Immune Sciences (NASDAQ:ALPN) from a buy rating to a hold rating in a research note published on Friday morning, Zacks.com reports.

According to Zacks, “Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington. “

Other analysts have also recently issued reports about the company. ValuEngine cut Alpine Immune Sciences from a hold rating to a sell rating in a research note on Friday, January 11th. Oppenheimer set a $13.00 price target on Alpine Immune Sciences and gave the company a buy rating in a research note on Tuesday, March 19th. Finally, restated a buy rating and issued a $13.00 price target on shares of Alpine Immune Sciences in a research note on Tuesday, February 12th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $12.07.



Shares of NASDAQ ALPN opened at $5.90 on Friday. The firm has a market capitalization of $82.58 million, a PE ratio of -2.24 and a beta of 2.06. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.59 and a current ratio of 6.59. Alpine Immune Sciences has a 12-month low of $3.66 and a 12-month high of $10.57.

Alpine Immune Sciences (NASDAQ:ALPN) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($0.01). As a group, analysts anticipate that Alpine Immune Sciences will post -2.71 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc raised its stake in Alpine Immune Sciences by 5.2% in the third quarter. Vanguard Group Inc now owns 227,834 shares of the biotechnology company’s stock valued at $1,442,000 after buying an additional 11,200 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of Alpine Immune Sciences by 109.0% during the fourth quarter. Victory Capital Management Inc. now owns 136,072 shares of the biotechnology company’s stock worth $501,000 after purchasing an additional 70,980 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Alpine Immune Sciences by 5.2% during the third quarter. Vanguard Group Inc. now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after purchasing an additional 11,200 shares during the last quarter. Hikari Power Ltd purchased a new position in shares of Alpine Immune Sciences during the fourth quarter worth about $453,000. Finally, Raymond James & Associates purchased a new position in shares of Alpine Immune Sciences during the first quarter worth about $94,000. Institutional investors own 53.79% of the company’s stock.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.

Further Reading: Outstanding Shares and The Effect on Share Price

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.